<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059448</url>
  </required_header>
  <id_info>
    <org_study_id>20090402</org_study_id>
    <nct_id>NCT01059448</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of AMG 827 in Subjects With RA</brief_title>
  <official_title>A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      This is an extension study for subjects who participated in Protocol 20090061 (NCT00950989).&#xD;
      All subjects in this study will receive a 210mg injection of AMG827 for treatment for their&#xD;
      Rheumatoid Arthritis for up to 5 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy for Brodalumab in Rheumatoid Arthritis (RA)&#xD;
  </why_stopped>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of long-term exposure with AMG 827 is subjects with rheumatoid arthritis.</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of AMG 827 as measured by the proportion of subjects achieving an American College of Rheumatology (ACR) 20, 50, and 70 response</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of AMG 827 as measured by the change in Disease Activity Score 28 joint (DAS28) score</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of AMG 827 as measured by the proportion of subjects with DAS28&lt;2.6</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of AMG 827 as measured by the DAS28 score</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of AMG 827 as measured by the ACR individual components</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of treatment on patient-reported outcomes, including the Medical Outcomes Short Form-36 (SF-36), Medical Outcomes Study (MOS) Sleep Scale, and Health Assessment Questionnaire Disability Index (HAQ-DI)</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the proportion of subjects who develop anti-AMG 827 anti-bodies</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore lipid profiles in subjects receiving AMG 827</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>210mg AMG 827</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 827 210mg at baseline, week 1, week2, and every 2 weeks thereafter</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 827</intervention_name>
    <description>AMG 827 210 mg</description>
    <arm_group_label>210mg AMG 827</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has provided informed consent.&#xD;
&#xD;
          -  Subject was randomized into study 20090061 and completed the week 16 evaluation.&#xD;
&#xD;
          -  Negative test for hepatitis B virus (HBV) surface antigen, hepatitis C virus (HCV)&#xD;
             antibody, and/or human immunodeficiency virus (HIV) in subjects if clinically&#xD;
             indicated (eg, known recent exposure) in the opinion of the investigator.&#xD;
&#xD;
          -  Subject must test negative for Tuberculosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject had any SAE reported during 20090061 that was considered to be related to IP.&#xD;
&#xD;
          -  Subject is currently experiencing an infection of CTCAE grade 2 (if requiring oral&#xD;
             antibiotics) or higher. Subject is ineligible until the infection is resolved in the&#xD;
             opinion of the investigator.&#xD;
&#xD;
          -  For subjects with &gt; 4 weeks between the week 16 visit of 20090061 and the planned&#xD;
             first IP dose in 20090402, subject has laboratory abnormalities at screening,&#xD;
             including:&#xD;
&#xD;
          -  Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT); &gt;1.5x&#xD;
             upper limit of normal)&#xD;
&#xD;
          -  Serum total bilirubin ≥1.5 mg/dL&#xD;
&#xD;
          -  Hemoglobin &lt; 11 g/dL&#xD;
&#xD;
          -  Platelet count &lt; 125,000 /mm3&#xD;
&#xD;
          -  White blood cell count &lt; 3,000 cells/mm3&#xD;
&#xD;
          -  Absolute neutrophil count &lt; 2000/mm3&#xD;
&#xD;
          -  Estimated creatinine clearance &lt; 50 mL/min (Cockroft-Gault formula, central lab will&#xD;
             calculate value and provide to sites)&#xD;
&#xD;
          -  Subject has a significant concurrent medical conditions, including:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Poorly controlled type 2 diabetes (Hemoglobin A1c &gt; 8.5)&#xD;
&#xD;
          -  Symptomatic heart failure (New York Heart Association class II, III, or IV)&#xD;
&#xD;
          -  Myocardial infarction within the last year&#xD;
&#xD;
          -  Current or history of unstable angina pectoris within the last year&#xD;
&#xD;
          -  Uncontrolled hypertension as defined by resting blood pressure &gt; 150/90 mmHg prior to&#xD;
             first IP dose (confirmed by a repeat assessment)&#xD;
&#xD;
          -  Severe chronic pulmonary disease (eg, requiring oxygen therapy)&#xD;
&#xD;
          -  Major chronic inflammatory disease or connective tissue disease other than rheumatoid&#xD;
             arthritis (eg, systemic lupus erythematosus), with the exception of secondary&#xD;
             Sjögren's syndrome&#xD;
&#xD;
          -  Multiple sclerosis or any other demyelinating disease&#xD;
&#xD;
          -  Active malignancy, including evidence of cutaneous basal or squamous cell carcinoma or&#xD;
             melanoma, or history of cancer (except successfully treated in situ cervical cancer or&#xD;
             squamous or basal cell carcinoma of the skin)&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, might cause this study to be&#xD;
             detrimental to the subject&#xD;
&#xD;
          -  Subject is pregnant or breast feeding, or planning to become pregnant while enrolled&#xD;
             in the study, up to the subject's last study visit including the follow-up period.&#xD;
&#xD;
          -  Female subject is not willing to abstain from sexual intercourse or use 2 highly&#xD;
             effective forms of birth control for the duration of the study and at least 40 days&#xD;
             after the last dose (except women at least 3 years postmenopausal or surgically&#xD;
             sterile). Highly effective methods of birth control for women include but are not&#xD;
             limited to birth control pills, Depo Provera® injections, contraceptive implants, or&#xD;
             occlusive cap (barrier method) in combination with barrier methods used by the man.&#xD;
&#xD;
          -  Male subject is not willing to abstain from sexual intercourse or use 2 highly&#xD;
             effective forms of birth control for the duration of the study, plus an additional 16&#xD;
             weeks after the last dose (except for men who are surgically sterile or whose female&#xD;
             partners are at least 3 years postmenopausal or surgically sterile). Highly effective&#xD;
             methods of birth control include but are not limited to a condom in combination with&#xD;
             hormonal birth control or barrier methods used by the woman.&#xD;
&#xD;
          -  Male subject (including vasectomised males) with a pregnant female partner is not&#xD;
             willing to use effective methods to ensure that an unborn child is not exposed to AMG&#xD;
             827 via semen. Effective methods to ensure that an unborn child is not exposed to AMG&#xD;
             827 via semen include condoms or abstinence.&#xD;
&#xD;
          -  Subject has used any of the following within 14 days prior to IP initiation&#xD;
&#xD;
          -  Non-biologic disease-modifying anti-rheumatic drugs (DMARD) other than as allowed in&#xD;
             20090061&#xD;
&#xD;
          -  Intra-articular, intramuscular, or intravenous corticosteroids, including&#xD;
             adrenocorticotropic hormone&#xD;
&#xD;
          -  Subject has used any of the following within 3 months prior to IP initiation&#xD;
&#xD;
          -  Leflunomide&#xD;
&#xD;
          -  Live vaccines&#xD;
&#xD;
          -  Commercially available or experimental biologic DMARD except for AMG 827&#xD;
&#xD;
          -  Subject has received gold therapy within 6 months prior to IP initiation.&#xD;
&#xD;
          -  Subject received another investigational agent (other than AMG 827) or participated in&#xD;
             an investigational device study subsequent to 20090061.&#xD;
&#xD;
          -  Other investigational procedures are excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <zip>92395</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rock Island</city>
        <state>Illinois</state>
        <zip>61201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1709</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3N 0K6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 11</city>
        <zip>148 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 59</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bauska</city>
        <zip>3901</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daugavpils</city>
        <zip>5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liepaja</city>
        <zip>3400</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>1006</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tijuana</city>
        <state>Baja Calif</state>
        <zip>22010</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito F</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito F</state>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morelia</city>
        <state>MichoacÃ¡n</state>
        <zip>58070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Luis Potosi</city>
        <state>San Luis P</state>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-461</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-607</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-356</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>ToruÅ&quot;</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zyrardow</city>
        <zip>96-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Merseyside</city>
        <zip>L49 5PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2010</study_first_posted>
  <disposition_first_submitted>April 6, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 27, 2015</disposition_first_posted>
  <last_update_submitted>August 14, 2015</last_update_submitted>
  <last_update_submitted_qc>August 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amgen</keyword>
  <keyword>RA</keyword>
  <keyword>AMG 827</keyword>
  <keyword>20090061</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brodalumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

